A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®면역 저하 환자에서 승인된 SARS-CoV-2 백신을 평가하기 위한 시험 플랫폼: mRNA 백신 Comirnaty®와 COVID-19 mRNA를 비교하는 파일럿 시험을 위한 첫 번째 하위 프로토콜 Vaccine Moderna®Study Protocol Published on 2021-10-212022-09-10 Journal: Trials [Category] MERS, SARS, 임상, [키워드] Antibody Response approaches approved baseline clinical trial Cohort cohorts collected data confidence interval contagious Controlled trial coronavirus coronavirus SARS-CoV-2 COVID-19 disease Efficacy Efficacy and safety eligible Endpoint endpoints favor feasibility first vaccination flexible foundation Frame groups highest HIV HIV patient HIV patients Immunocompromised Immunocompromised patient Immunocompromised patients information Intervention Medical conditions Missing data mRNA mRNA vaccine multicenter non-inferiority margin Open-label Organ transplant outcome pandemic Patient patient recruitment Pfizer/BioNTech pilot study Platform trial positive antibody response primary clinical outcome Program proportion protocol randomization Randomized Randomized controlled trial Randomized controlled trial, HIV RCT reached reactivity receiving recipients required Sample size SARS-CoV-2 SARS-CoV-2 vaccine Science Statistical power STCS Switzerland Transplant treatment arm Trial trial platform Trial registration two-sided type I type I error Vaccine Wuhan Wuhan, China [DOI] 10.1186/s13063-021-05664-0 PMC 바로가기 [Article Type] Study Protocol
Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for EnglandResearch Article Published on 2021-10-182022-10-28 Journal: BMC Medicine [Category] COVID-19, MERS, SARS, [키워드] 95% confidence interval acute illness adjusted Admission age BNT162b2 mRNA vaccine Care case control study caused clinical trials Community Concentration Control COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 symptom Deprivation dose Effect effective Effectiveness eligibility eligible Emergency England event Evidence first dose first vaccination Gender Health status Hospital admission hospitalisation individual infections less mRNA mRNA vaccine NHS observational study of BNT162b2 Older participant positive COVID-19 receipt receive recipient reduced reducing Result seasonal flu second dose Selection bias serious COVID-19 shown subsequent supplementary material the vaccine threshold vaccinated individual vaccination Vaccine Vaccines [DOI] 10.1186/s12916-021-02149-4 PMC 바로가기 [Article Type] Research Article
The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in JapanGlobal Health Published on 2021-10-132022-10-28 Journal: PeerJ [Category] COVID-19, [키워드] Administered administration Affect affecting age Analysis anti-SARS-CoV-2 antibody antibody production Antibody Response Antibody test Antibody titer Autoimmune disease blood sugar BMI BNT162b2 BNT162b2 vaccine calculated Cancer carried Corporation COVID-19 defined develop diabetes Effect evaluate Factor first vaccination groups hypertension Japan lack less likelihood Logistic regression analysis Lung disease mean value multivariate multivariate logistic regression no significant difference Older participant per day performed promoted proportion Prospective Study responses second vaccination significantly significantly higher single-center study Spike-specific antibody suppressor the median Tokyo vaccination Vaccination strategies Vaccine [DOI] 10.7717/peerj.12316 PMC 바로가기 [Article Type] Global Health
Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 VaccinationBrief Report Published on 2021-10-082022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] age antibodies antibody Antibody titer blood sample BNT162 vaccine BNT162b2 BNT162b2 vaccine collected decrease determine Efficacy and safety expected first vaccination Gender Health care worker help Month Neutralizing antibodies neutralizing antibody SARS-CoV-2 second vaccination significant decrease significantly titer vaccination Vaccinations vaccine immunogenicity were measured [DOI] 10.3390/vaccines9101145 PMC 바로가기 [Article Type] Brief Report
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection statusOriginal Article Published on 2021-10-012022-10-31 Journal: Clinical microbiology and infection : the official [Category] COVID-19, MERS, SARS, [키워드] Abbott SARS-CoV-2 IgG acute respiratory syndrome Anti-spike anti-spike antibody anti-spike antibody response anti-spike IgG response antibody Antibody Response Antibody testing coronavirus detectable determinant dose dosing interval Efficacy Evidence first dose first vaccination HCW HCWs healthcare worker identify Infection investigated median multivariable logistic regression objective Pfizer Pfizer–BioNTech predictor Quantitative anti-spike antibody receiving recipient recipients response Result SARS-CoV-2 SARS-CoV-2 PCR SARS-CoV-2 vaccination second vaccination Serological testing serology seropositive Sex tested vaccination Vaccine vaccine dose Vaccines were measured [DOI] 10.1016/j.cmi.2021.05.041 PMC 바로가기 [Article Type] Original Article
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases면역 매개 염증성 질환을 가진 치료되지 않고, 통상적으로 치료되고, 항사이토카인 치료를 받는 환자에서 SARS-CoV-2 백신 접종 반응Article Published on 2021-10-012022-09-12 Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 진단, [키워드] 95% CI adjusted age analysed anti-SARS-CoV-2 IgG baseline biological therapy concomitant treatment Control COVID-19 demographic develop Epidemiology Estimated Factor first vaccination FIVE humoral immune response Immune-mediated inflammatory disease marginal mean neutralising antibody activity Patient reduced response responses against SARS-CoV-2 SARS-CoV-2 vaccination serum Sex the disease the SARS-CoV-2 treated treated patient vaccination vaccination response were measured were recorded while [DOI] 10.1136/annrheumdis-2021-220461 PMC 바로가기 [Article Type] Article
Sex Differences in Adverse Reactions to an Inactivated SARS-CoV-2 Vaccine Among Medical Staff in ChinaMedicine Published on 2021-09-082022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] Adverse Adverse reaction Adverse reactions China conducted confounding factors COVID-19 COVID-19 vaccine cross-sectional survey demonstrated difference Factor first vaccination Frequency hospital inactivated Inactivated vaccine increased the risk Influenza injection Injections investigated knowledge medical staff men participated questionnaire reaction receiving reported SARS-CoV-2 SARS-CoV-2 vaccine second vaccination Sex difference significantly the vaccine vaccination Vaccine Vaccines women [DOI] 10.3389/fmed.2021.731593 PMC 바로가기 [Article Type] Medicine
SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection과거 자연 감염이 있는 사람의 BNT162b2 mRNA 백신에 대한 SARS-CoV-2 항체 반응Case Reports Published on 2021-09-062022-09-12 Journal: Journal of Korean medical science [Category] SARS, 진단, [키워드] acute respiratory syndrome Administered Admission adverse events Anti-spike antibody Antibody Response Antibody titer Asymptomatic blood test BNT162b2 BNT162b2 mRNA BNT162b2 vaccine chest X-ray Clinical course coronavirus coronavirus disease COVID-19 COVID-19 symptoms COVID-19 vaccine discharge domain first vaccination HCW HCWs healthcare worker Immunoglobulin infected patients infiltration Isolation Mild mRNA vaccination natural natural infection Neutralizing antibodies neutralizing antibody Patient patients performed Person Protein quarantine reaction response SARS-CoV-2 second dose second vaccination seropositive signal specific treatment suffered Symptom Total upper respiratory infection vaccination Vaccine [DOI] 10.3346/jkms.2021.36.e250 PMC 바로가기 [Article Type] Case Reports
Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals백신 접종 후 COVID-19: 부분 백신 접종을 받은 개인의 119개 돌발성 감염에 대한 사례 대조 연구 및 게놈 분석Major Article Published on 2021-08-192022-09-10 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 유전자 메커니즘, 치료기술, [키워드] 95%CI Admission age and sex all-cause mortality allele Analysis B.1.1.7 B.1.525 BNT162b2 BNT162b2 mRNA Breakthrough infection case-control study ChAdOx1 ChAdOx1 nCoV-19 Control COVID-19 COVID-19 pandemic Ct values died difference dose E484K escape mutation evaluated first vaccination Genome sequencing Genomic analysis genomic change Genomics hospital Hospital admission Hospital admissions Infection IQR Lineage median Mortality Mutation NNT nucleotide Patient patients with COVID-19 Phylogenetic polymorphism predominant reduce reduction in mortality Relative risk Result risk RR reduction SARS-COV-2 infection single nucleotide Single nucleotide polymorphism SNP subgroup subgroup analysis treat vaccinated individual vaccination Vaccine variant was performed with infection [DOI] 10.1093/cid/ciab714 PMC 바로가기 [Article Type] Major Article
Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in GermanyArticle Published on 2021-08-162022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adverse effects age age and gender age- and sex-graded data evaluation BNT162b2 BNT162b2 mRNA carried center coronavirus COVID-19 COVID-19 vaccination Data analysis Effectiveness examined Factor female first dose first vaccination Germany groups Immunity individual initial Local male mRNA mRNA vaccine mRNA vaccine BNT162b2 Older older population pandemic reaction Reactions reported Sex side Side effects study population systemic side effect Tolerance vaccination vaccination rate vaccination side effects Vaccination strategies Vaccination strategy Vaccine women [DOI] 10.3390/vaccines9080911 PMC 바로가기 [Article Type] Article